Here's Why Nobody's Happy About This $63 Billion Buyout

AbbVie (NYSE: ABBV) investors leery about the company's acquisition decisions quickly sliced $18.8 billion from the pharmaceutical company's market cap after AbbVie announced it's getting into the business at their expense. You might expect Allergan (NYSE: AGN) shareholders to be pleased with a $60 billion buyout offer that pushed the stock 26% higher, but they're fuming, too.